Portal de Periódicos da CAPES

Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere ® ) in patients with neovascular age‑related macular degeneration

2020; Spandidos Publishing; Volume: 20; Issue: 6 Linguagem: Inglês

10.3892/etm.2020.9291

1792-1015

Daniel Benisek, Julio Manzitti, Daniel H. Scorsetti, Andrés Rousselot Ascarza, Amalia Ascarza, Diego Gomez Rancaño, Romina Quercia, Matias Ramirez Gismondi, Mateo Carpio Total, M. Micaela Scorsetti, Eduardo Spitzer, C. Lombas, Matías Deprati, M Penna, F. FERNÁNDEZ, Marcelo Tinelli,

Ocular Diseases and Behçet’s Syndrome

The present study was an open‑label, prospective, uncontrolled and multicenter clinical trial to investigate the safety and effectiveness of bevacizumab (Lumiere ® ) administered by the intravitreal route for the treatment of neovascular age‑related macular degeneration (nAMD). A total of 22 patients without previous treatment with anti‑vascular endothelial growth factor were recruited. Monthly therapy with 1.25 mg intravitreal bevacizumab was applied. Adverse events (AE), visual acuity (VA) and central retinal thickness (CRT) were assessed at baseline, day 1 and day 28 after each injection. A total of 87 AEs were reported; most of them were not serious (96.6%), expected (65.5%) and occurred after the third injection (56.3%). The most frequent AE was ‘conjunctival hemorrhage’ (29.9% of AEs), attributed to the injection procedure. Treatment was not suspended due to safety reasons in any case. After six months, a statistically significant gain of +8.2 (SD±8.8) letters and a CRT reduction of ‑75.50 µm (SD±120.3) were achieved with unilateral therapy. VA improvement and CRT reduction ​​were also achieved with bilateral therapy, although to a lesser extent. The results of the present study suggested that therapy with a minimum of 3 doses of bevacizumab over a 6‑month period was well tolerated and resulted in a sustained response regarding VA improvement and CRT reduction from the beginning of therapy compared with the baseline value. The study protocol was registered at clinicaltrials.gov (ref. no. NCT03668054).